Results 21 to 30 of about 5,003,572 (301)

Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Haematologica, 2019
Therapeutic factor VIII is highly immunogenic. Despite intensive research in the last decades, the reasons why 5-30% of patients with hemophilia A (of all severities) develop inhibitory anti-factor VIII antibodies (inhibitors) following replacement ...
Aditi Varthaman, Sébastien Lacroix-Desmazes   +1 more
doaj   +1 more source

Acquired Factor VIII Deficiency Presenting as Gross Hematuria in a Hispanic, Pregnant Patient with Previously Undiagnosed Connective Tissue Disease

Case Reports in Rheumatology, 2021
Acquired factor VIII deficiency is a bleeding disorder caused by the presence of autoantibodies against clotting factor VIII. We report a case of a 24-year-old pregnant woman who presented with gross hematuria secondary to acquired factor VIII deficiency
Christine Loftis, Emilia C. Dulgheru, Rosa White   +2 more
doaj   +1 more source

HIGH FACTOR VIII AND CORONARY ARTERY DISEASE A CASE REPORT

, 2022
High factor VIII is the risk factor for venous thrombosis and coronary artery disease. Here we are presenting a case of coronary artery disease with high Factor VIII. Thrombophilia screening does not include screening of factor VIII.
Yasmeen Talal Abulkhair, Priyanka Agasimani   +1 more
core   +1 more source

Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A

Haematologica, 2015
A large fraction of factor VIII in blood originates from liver sinusoidal endothelial cells although extrahepatic sources also contribute to plasma factor VIII levels.
Diego Zanolini, Simone Merlin, Maria Feola, Gabriella Ranaldo, Angela Amoruso, Gianluca Gaidano, Mauro Zaffaroni, Alessandro Ferrero, Sandra Brunelleschi, Guido Valente, Sanjeev Gupta, Maria Prat, Antonia Follenzi   +12 more
doaj   +1 more source

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis

BMJ Open
Objectives Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how ...
Randall Curtis, Thomas Majda, Janet S. Lee, Stacey L. Kowal   +3 more
doaj   +1 more source

Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study

Research and Practice in Thrombosis and Haemostasis
Background: The SIPPET randomized clinical trial showed that in previously untreated patients (PUPs) with severe hemophilia A, treatment with plasma-derived factor (F)VIII (pdFVIII) within the first 50 exposure days (EDs) was associated with a lower ...
Syna Miri, Frits R. Rosendaal, Kaan Kavakli, Peyman Eshghi, Soha Mohammadi Moghaddam, Sara Scardo, Behnaz Habibpanah, Mohsen Elalfy, Susan Halimeh, Gabriella Nicolò, Dilek Gökçebay, Namık Özbek, Tiraje Celkan, Ahmad Mohammadi, Mehran Karimi, Amin Shahsavani, Bariş Yılmaz, Canan Albayrak, Burcak Gunes, Zühre Kaya, Yilmaz Ay, Sinan Akbayram, Nazan Sarper, Pier Mannuccio Mannucci, Flora Peyvandi   +24 more
doaj   +1 more source

Combined deficiencies of Factor VIII (AHF) and Factor XI (PTA)

, 1976
Combined deficiencies of Factor VIII and Factor XI associated with moderate degree of bleeding symptoms were found in 3 brothers. Examination of Factor VIII activity and Factor VIII-related antigen revealed that the Factor VIII activity/Factor VIII ...
Harkness, D R, Lian, E C, Deykin, D
core   +3 more sources

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice

Haematologica, 2018
Immune responses to factor VIII remain the greatest complication in the treatment of severe hemophilia A. Recent epidemiological evidence has highlighted that recombinant factor VIII produced in baby hamster kidney cells is more immunogenic than factor ...
Jesse D. Lai, Laura L. Swystun, Dominique Cartier, Kate Nesbitt, Cunjie Zhang, Christine Hough, James W. Dennis, David Lillicrap   +7 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Biphasic Clinical Course of Pediatric Cytomegalovirus‐Associated Immune Thrombocytopenia: Early Poor Treatment Response but Favorable Long‐Term Outcomes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cytomegalovirus (CMV) is a recognized trigger of immune thrombocytopenia (ITP); however, its incidence and impact on disease course in children remain controversial. Therefore, we aimed to characterize the clinical course of pediatric patients with CMV‐associated ITP.
Oded Gilad, Ohad Atia, Osama Tanous, Dafna Brik Simon, Michal Dvori, Miriam Cohen, Tracie A. Goldberg, Efraim Bilavsky, Joanne Yacobovich, Orna Steinberg‐Shemer   +9 more
wiley   +1 more source